Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma

Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in RRMM

Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia

Imetelstat provides durable transfusion independence in heavily transfused non-del(5q) LR-MDS R/R to ESAS

D-VTd in induction prior to and consolidation after ASCT improves PFS and depth of response with acceptable safety

Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities

Most pregnancies in CML patients resulted in normal childbirth: Analysis of 305 cases of the European Leukemia Net registry

Intervention for AML patients with MRD can result in improved survival

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma

Maintenance pembrolizumab vs placebo for metastatic urothelial cancer

NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer?

Comment: Chemotherapy for frail and elderly patients with advanced gastroesophageal cancer